Shuttle Pharmaceuticals (NASDAQ: SHPH), a rising force in cancer treatment innovation, has experienced a notable boost in its ...

Shuttle Pharmaceuticals (SHPH) announced that the first three patients in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of ...

The initial balance of the Note was $4.3 million and was originally repayable over a 26-month period ending March 11, 2025. During the term of the note, Shuttle Pharma made periodic cash payments ...

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty ...

As Shuttle Pharmaceuticals embarks on this critical trial, the implications for the cancer community are profound. A successful outcome could not only improve survival rates for glioblastoma patients ...

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty ...